If someone you love has been touched by Alzheimer's, or if you are thinking seriously about your own brain health as you age, you have probably gone looking for something you can actually do. Something grounded in real science. Something that fits into daily life without becoming another burden.
Gamma40 was made for that moment. Nine 60-minute ambient tracks, each delivering a precisely calibrated 40 Hz pulse. Put on headphones, press play, and go about your day.
It is a collection of nine 60-minute audio tracks, each one delivering a precisely calibrated 40 Hz auditory pulse embedded in a different ambient soundscape. You put on headphones, press play, and go about your day. The pulse is there with you throughout — a steady 40-beat rhythm running beneath the ambient sound, doing its work while you read, rest, or simply sit with a cup of tea.
The underlying research is real, peer-reviewed, and moving fast. Human trials are ongoing. We have built Gamma40 for people who want to engage with that science now, with clear eyes about where the evidence currently stands.
View the full research infographic →The brain naturally produces gamma oscillations at around 40 Hz during healthy cognitive activity. In Alzheimer's disease, these rhythms are disrupted.
Research from MIT's Tsai Lab first showed in 2016 that driving gamma oscillations externally using pulsed sound or light reduces amyloid load in mouse models of Alzheimer's. This approach became known as the GENUS protocol.
A 2026 study in PNAS (Wang et al.) provided the first primate evidence. After seven days of daily 40 Hz auditory stimulation, CSF amyloid levels in aged rhesus monkeys increased by more than 200%, indicating the brain was actively clearing amyloid via the glymphatic system. That elevated clearance persisted for over five weeks after stimulation ended — a duration unlike anything seen in prior rodent studies.
A 2024 study in Nature (Murdock et al.) confirmed the mechanism at the molecular level. Gamma stimulation triggers a chain involving VIP interneurons, arterial pulsatility, and AQP4 water channels in astrocytes, collectively driving glymphatic clearance.
Gamma40 tracks are built to match the exact stimulus used in the Wang et al. study: 1,000 Hz pure tones, pulsed at 40 Hz, at 1 ms per burst, at 60 dB SPL. Pulse frequency is validated at ±0.05 Hz by FFT analysis.
Download once to your phone, tablet, or computer. Play in Apple Music, VLC, or any app that plays MP3 or M4A files. No subscription. No account. No algorithm.
Wang et al.[1] exposed 9 aged rhesus monkeys (26–31 years old) to just 7 days of 40 Hz sound. CSF amyloid levels more than doubled and, critically, remained elevated for over 5 weeks after stimulation ended. This long-term effect had never been seen in any rodent study, suggesting fundamental species differences in how the glymphatic system responds.
Postmortem examination confirmed widespread amyloid plaques in all four examined brains, validating that the CSF changes were reflecting real pathological clearance rather than measurement artefact.
Read in PNAS 2026 →Murdock et al.[2] pinpointed the exact cascade: gamma stimulation triggers VIP interneurons → arterial pulsatility increases → AQP4 water channels in astrocytes open → CSF floods in → amyloid washes out. Blocking any step in the chain blocked clearance.
Nature 627, 149–156 →Chan, Tsai et al.[3] followed 5 mild AD patients for 30 months at MIT. Three late-onset patients maintained significantly higher cognition versus national AD databases. Two showed plasma pTau217 reduction, which is direct biomarker evidence of disease modification.
Alzheimer's & Dementia 2025 →Soula et al.[4] found that 40 Hz visual stimulation failed to entrain gamma oscillations or reduce Aβ in their AD mouse model. This important null result challenges the rodent evidence base, which is exactly why the primate data from Wang 2026[1] matters so much. We need species that actually develop AD naturally.
Nat Neurosci 26, 570–578 →Cognito Therapeutics' Spectris AD device, a wearable 40 Hz audiovisual headset, is in the largest Alzheimer's device trial in history.[5] 670 patients, 70 US sites, 12-month treatment phase. Results expected 2026–2027 and will be definitive for whether this approach gains clinical approval.
NCT05637801 ↗Martorell et al.[6] showed that the auditory cortex, sitting in the temporal lobe — the region most severely affected by Alzheimer's pathology — is activated directly by sound. Visual stimulation targets the occipital cortex instead. That anatomical advantage makes audio-first stimulation a compelling therapeutic pathway.
Cell 177, 256–271 →Download the free 10-minute sample, calibrate your headphones, and experience the protocol yourself. No app. No account. Just the science, in your ears.
Gamma40 is a general wellness application. It is not a medical device and has not been approved by the FDA, TGA, or any regulatory body to treat, diagnose, cure or prevent any disease. Consult your physician before use if you have epilepsy, cochlear implants, or are under neurological treatment. Evidence supporting 40 Hz stimulation is promising but Phase 3 clinical trials are ongoing.